Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B44d2f6eb21a5f55760cb3c176f82e312> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B44d2f6eb21a5f55760cb3c176f82e312 NCIT_P378 "NCI" @default.
- B44d2f6eb21a5f55760cb3c176f82e312 type Axiom @default.
- B44d2f6eb21a5f55760cb3c176f82e312 annotatedProperty IAO_0000115 @default.
- B44d2f6eb21a5f55760cb3c176f82e312 annotatedSource NCIT_C104048 @default.
- B44d2f6eb21a5f55760cb3c176f82e312 annotatedTarget "A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone." @default.